Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Back to Reality Boys/Girls

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Nov 09, 2020 4:20pm

55 Views

Post# 31864904

RE:RE:RE:RE:Back to Reality Boys/Girls

Ingiboy, I think you are spot on. I think this will be a needle mover and larger than YOFOTO. Lee has been talking about a new partnership for the better party of the last 8-12 months...perhaps it's finally coming to fruition

and for reference, YOFOTO news popped to .45¢
(P.s. I trade in the US and my reference is USD, on REPCF)

P.P.S - I love the positive activity with this chatter & Replicels Twitter account. I can't help but get excited for the balance of the year

<< Previous

Bullboard Posts

Next >>

These are Canada's top construction stocks